What is Masimo?
Founded in 1989 by Joe Kiani, Masimo Corporation has evolved into a powerhouse of medical innovation, headquartered in Irvine, California. The company is widely recognized for its Signal Extraction Technology, which fundamentally transformed pulse oximetry by providing accurate readings during patient motion and low perfusion. Beyond its core oximetry business, Masimo has diversified its portfolio to include advanced medical devices, sensors, and comprehensive hospital connectivity solutions.
The company's market position is defined by its ability to bridge the gap between clinical-grade monitoring and home healthcare settings. Through its focus on noninvasive technologies, Masimo has successfully integrated its systems into hospital workflows globally, driving improvements in patient outcomes and operational efficiency. Its commitment to research and development remains a primary driver of its sustained growth and industry influence.
How much funding has Masimo raised?
Masimo has raised a total of $387.9M across 3 funding rounds:
Stock Offering
$233M
Grant
$5M
Debt
$150M
Stock Issuance/Offering (2007): $233M with participation from Undisclosed
Grant (2016): $5M led by Bill & Melinda Gates Foundation
Debt (2018): $150M supported by JP Morgan Chase and Bank of the West
Key Investors in Masimo
Bill & Melinda Gates Foundation
A global philanthropic organization dedicated to improving healthcare outcomes and reducing extreme poverty through strategic grants and partnerships.
JP Morgan Chase
A leading global financial services firm providing comprehensive investment banking and debt financing solutions to large-scale enterprises.
Bank of the West
A financial institution offering specialized commercial banking services and capital support for established corporate entities.
What's next for Masimo?
Looking ahead, Masimo is poised to leverage its recent capital influx to accelerate the deployment of its telehealth platforms and hospital automation suites. As the healthcare industry shifts toward decentralized care models, the company's expertise in remote patient monitoring positions it to capture significant market share in the digital health sector.
Strategic priorities likely include the expansion of its sensor technology applications and the integration of artificial intelligence into its existing monitoring ecosystems. By maintaining a focus on high-growth segments such as hospital connectivity and consumer-facing health devices, Masimo is well-equipped to navigate the complexities of the evolving medical landscape while delivering long-term value to its stakeholders.
